Minireviews
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Aug 10, 2014; 5(3): 546-553
Published online Aug 10, 2014. doi: 10.5306/wjco.v5.i3.546
Pleomorphic lobular carcinoma in situ of the breast: Can the evidence guide practice?
Andrew Pieri, James Harvey, Nigel Bundred
Andrew Pieri, Wansbeck General Hospital, Northumbria, NE63 9JJ, United Kingdom
James Harvey, Nigel Bundred, Nightingale Centre, University Hospital of South Manchester, Wythenshawe Hospital, Manchester, M23 9LT, United Kingdom
Author contributions: Pieri A, Harvey J and Bundred N designed the review; Pieri A performed the systematic search; Pieri A and Harvey J assessed the quality of the studies; Pieri A analysed the data from the included studies; Pieri A, Harvey J and Bundred N wrote the paper.
Correspondence to: Nigel Bundred, MD, FRCS, Professor of Surgical Oncology, Nightingale Centre, University Hospital of South Manchester, Wythenshawe Hospital, Southmoor Road, Manchester, M23 9LT, United Kingdom. nigel.j.bundred@manchester.ac.uk
Telephone: +44-161-2915859 Fax: +44-161-2915860
Received: February 22, 2014
Revised: April 20, 2014
Accepted: June 10, 2014
Published online: August 10, 2014
Processing time: 159 Days and 23.1 Hours
Core Tip

Core tip: Pleomorphic lobular carcinoma in situ (PLCIS) is a breast lesion, the clinical significance of which is a subject of controversy. To date, this systematic review is the largest pooled series of clinical data regarding PLCIS. We aimed to establish whether current guidelines for management are consistent with the evidence. The results demonstrate a lack of high quality data and guidelines for management are variable. Analysis revealed a high incidence of concurrent invasive disease with PLCIS (49%) and following excision, a recurrence rate of 9.4%. We conclude that it would seem prudent to manage PLCIS as with ductal carcinoma in situ, although there is a dire need for long-term outcome studies.